iData Insights

Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 16:59 IST

Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015 Summary Global Markets Direct s, Streptococcus Pneumoniae Infection - Pipeline Review, H2 2015 , provides an overview of the Streptococcus Pneumoniae Infection s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pneumoniae Infection and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Streptococcus Pneumoniae Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Streptococcus Pneumoniae Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Streptococcus Pneumoniae Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 8

Global Markets Direct Report Coverage 8

Streptococcus Pneumoniae Infection Overview 9

Therapeutics Development 10

Pipeline Products for Streptococcus Pneumoniae Infection - Overview 10

Pipeline Products for Streptococcus Pneumoniae Infection - Comparative Analysis 11

Streptococcus Pneumoniae Infection - Therapeutics under Development by Companies 12

Streptococcus Pneumoniae Infection - Therapeutics under Investigation by Universities/Institutes 16

Streptococcus Pneumoniae Infection - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Streptococcus Pneumoniae Infection - Products under Development by Companies 20

Streptococcus Pneumoniae Infection - Products under Investigation by Universities/Institutes 23

Streptococcus Pneumoniae Infection - Companies Involved in Therapeutics Development 24

Abera Bioscience AB 24

Allergan Plc 25

Alvogen Korea 26

Arsanis Biosciences GmbH 27

AstraZeneca Plc 28

Beijing Minhai Biotechnology Co., Ltd 29

ContraFect Corporation 30

Daiichi Sankyo Company, Limited 31

Eurocine Vaccines AB 32

FluGen, Inc. 33

GlaxoSmithKline Plc 34

ImmunoBiology Limited 35

Lascco SA 36

Liquidia Technologies, Inc. 37

Melinta Therapeutics, Inc 38

Merck & Co., Inc. 39

Mucosis B.V. 40

Panacea Biotec Limited 41

Prometheon Pharma, LLC 42

Sanofi Pasteur SA 43

Serum Institute of India Limited 44

Sinovac Biotech Ltd. 45

SK Chemicals Co., Ltd. 46

Sumitomo Dainippon Pharma Co., Ltd. 47

Valneva SE 48

Vaxxilon AG 49

Virometix AG 50

Walvax Biotechnology Co., Ltd. 51

Wellstat Vaccines, LLC 52

Wockhardt Limited 53

Streptococcus Pneumoniae Infection - Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Combination Products 55

Assessment by Target 56

Assessment by Mechanism of Action 58

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

Ab-01 - Drug Profile 64

acorafloxacin hydrochloride - Drug Profile 65

Antibodies for Pneumococcus Infections - Drug Profile 68

ASN-400 - Drug Profile 69

AZ-6142 - Drug Profile 70

CAL-02 - Drug Profile 71

CF-303 - Drug Profile 72

CF-309 - Drug Profile 73

DEF-201 - Drug Profile 74

GSK-2189242A - Drug Profile 76

GSK-2830929A - Drug Profile 77

GSK-2830930A - Drug Profile 78

LCB-010371 - Drug Profile 79

Monoclonal Antibodies to Inhibit ADAM10 for Dermatology, Infectious Diseases and Respiratory Disorders - Drug Profile 81

Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile 82

NBP-606 - Drug Profile 83

Nucovac - Drug Profile 84

pneumococcal (13-valent) vaccine - Drug Profile 85

pneumococcal (13-valent) vaccine - Drug Profile 86

pneumococcal (23-valent) vaccine - Drug Profile 87

pneumococcal (monovalent) vaccine - Drug Profile 88

pneumococcal (trivalent) vaccine - Drug Profile 89

pneumococcal [serotype 4 and 6A] vaccine - Drug Profile 90

pneumococcal [TIGR4] vaccine - Drug Profile 91

pneumococcal polysaccharide (13-valent) vaccine - Drug Profile 92

pneumococcal polysaccharide (23-valent) vaccine - Drug Profile 93

pneumococcal vaccine - Drug Profile 94

pneumococcal vaccine - Drug Profile 95

pneumococcal vaccine - Drug Profile 96

pneumococcal vaccine - Drug Profile 97

pneumococcal vaccine - Drug Profile 98

pneumococcal vaccine - Drug Profile 99

pneumococcal vaccine - Drug Profile 100

pneumococcal vaccine - Drug Profile 101

pneumococcal vaccine - Drug Profile 102

pneumococcal vaccine - Drug Profile 103

pneumococcus vaccine - Drug Profile 104

PneumoMab - Drug Profile 105

PnuBioVax - Drug Profile 106

PPV-23 - Drug Profile 107

RXP-873 - Drug Profile 108

SIILPCV-10 - Drug Profile 109

SM-295291 - Drug Profile 110

SM-369926 - Drug Profile 111

Small Molecule for Respiratory Tract Infections - Drug Profile 112

Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections - Drug Profile 113

Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia - Drug Profile 114

Small Molecules for Streptococcus Pneumoniae Infections - Drug Profile 115

Small Molecules to Inhibit CBPs for Pneumococcus Infections - Drug Profile 116

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 117

streptococcal pneumoniae vaccine - Drug Profile 118

streptococci pneumoniae vaccine - Drug Profile 119

streptococcus pneumonia vaccine - Drug Profile 120

streptococcus pneumoniae vaccine - Drug Profile 121

streptococcus pneumoniae vaccine (whole-cell) - Drug Profile 122

Synthetic Peptides for Bacterial Infections - Drug Profile 124

typhoid + pneumococcal vaccine - Drug Profile 125

V-114 - Drug Profile 126

VMT-1 - Drug Profile 127

WCK-4873 - Drug Profile 128

Streptococcus Pneumoniae Infection - Recent Pipeline Updates 129

Streptococcus Pneumoniae Infection - Dormant Projects 135

Streptococcus Pneumoniae Infection - Discontinued Products 138

Streptococcus Pneumoniae Infection - Product Development Milestones 139

Featured News & Press Releases 139

Appendix 146

Methodology 146

Coverage 146

Secondary Research 146

Primary Research 146

Expert Panel Validation 146

Contact Us 146

Disclaimer 147"

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects